Gravis" (Press release). Argenx. 17 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021. "Argenx Announces U.S. Food...
17 KB (1,326 words) - 07:06, 25 June 2024
text from this source, which is in the public domain. "Halozyme Announces argenx Receives FDA Approval for Vyvgart Hytrulo With Enhanze for Subcutaneous...
6 KB (425 words) - 07:18, 25 June 2024
"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Argenx (Press...
84 KB (8,872 words) - 02:44, 5 September 2024
text from this source, which is in the public domain. "Halozyme Announces argenx Receives FDA Approval for Vyvgart Hytrulo With Enhanze for Subcutaneous...
31 KB (2,902 words) - 11:13, 6 August 2024
cancers. In the same month the company announced it would co-commercialize Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy...
41 KB (3,428 words) - 02:11, 30 August 2024
Vulgaris therapeutics include Principia Biopharma, Topas Therapeutics and Argenx BVBA.[citation needed] Rituximab demonstrated superior efficacy compared...
17 KB (1,943 words) - 19:27, 8 September 2024
2022). "AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdown". Fierce Pharma. Archived from the original on 9 April 2022. Retrieved...
44 KB (3,805 words) - 00:43, 23 July 2024
AkzoNobel Amsterdam Alstom Paris Altice Paris ArcelorMittal Amsterdam, Paris Argenx Brussels Arkema Paris ASM International Amsterdam ASML Amsterdam AXA Paris...
7 KB (117 words) - 01:02, 20 May 2024
"argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Argenx. 17...
36 KB (4,071 words) - 16:46, 6 April 2024
Biotech portfolio as of June 30, 2024 included Ionis Pharmaceuticals (13.0%), Argenx (9.8%), Neurocrine Biosciences (8.6%), Vertex (8.1%), Alnylam Pharmaceuticals...
14 KB (980 words) - 07:10, 6 September 2024